Hjem › Diffust stort B-celle lymfom › Pennsylvania › Philadelphia
Diffust stort B-celle lymfom kliniske forsøg i Philadelphia, PA
15 studier for Diffust stort B-celle lymfom søger deltagere på steder i og omkring Philadelphia (inden for ca. 30 miles). Åbn et studie for at se, hvem der kan deltage, og hvordan man kontakter studieteamet.
Officiel studietekst (engelsk)
Rekrutterer til et studie her? Få det vist øverst på siden — $99 i 30 dage →
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
RekruttererFase 2
- Fox Chase Cancer Center, Philadelphia
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RekruttererObservationsstudie
- Children's Hospital of Philadelphia, Philadelphia
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
RekruttererFase 2
- Thomas Jefferson University Hospital, Philadelphia
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
RekruttererFase 2/3
- Alliance Cancer Specialists (ACS) ( Site 8001), Horsham · 16 mi væk
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
RekruttererFase 2
- Abramson Cancer Center and Perelman Center for Advanced Medicine ( Site 0131), Philadelphia
- Temple University Hospital ( Site 0133), Philadelphia
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RekruttererFase 1
- University of Pennsylvania Abramson Cancer Center, Philadelphia
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
RekruttererFase 1/2
- Children's Hospital of Philadelphia (CHOP) ( Site 1021), Philadelphia
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
RekruttererFase 1/2
- Thomas Jefferson University, Philadelphia
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
RekruttererFase 1/2
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
RekruttererFase 1
- University of Pennsylvania / Abramson Cancer Center, Philadelphia
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
RekruttererFase 1
- University of Pennsylvania, Abramson Cancer Center, Philadelphia
Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas
RekruttererFase 1
- Abramson Cancer Center, University of Pennsylvania, Philadelphia
Epcoritamab-CAR T Cells for Large B-cell Lymphomas
RekruttererFase 2
- Abramson Cancer Center at the University of Pennsylvania, Philadelphia
SynKIR-310 for Relapsed/Refractory B-NHL
RekruttererFase 1
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
RekruttererFase 2
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
Diffust stort B-celle lymfom forsøg i andre byer
- New York City, NY21 studier
- Baldwin Park, CA19 studier
- Chicago, IL18 studier
- Houston, TX17 studier
- Los Angeles, CA17 studier
- Boston, MA16 studier
- Milwaukee, WI16 studier
- Nashville, TN15 studier
- Portland, OR15 studier
- Durham, NC14 studier
- Dallas, TX13 studier
- Seattle, WA12 studier
Andre studier i Philadelphia
- Kræft (alle typer)59 studier
- Brystkræft56 studier
- Ikke-småcellet lungecancer51 studier
- Metastatisk cancer46 studier
- Colorektal kræft44 studier
- Ægstockræft44 studier
- Prostatakræft44 studier
- Lungecancer36 studier
- Akut myeloid leukæmi34 studier
- Hjertesvigt31 studier
- Livmoderslimhindekræft28 studier
- Depression26 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.